Diabetes and Heart Disease. The Connection Most Men Don't Fully Understand.

Type 2 diabetes is not primarily a disease of blood sugar. It is a cardiovascular disease that manifests as blood sugar elevation downstream of the actual problem. The most common cause of death in men with type 2 diabetes is cardiovascular disease, not hypoglycemia, not kidney failure, not neuropathy. It is heart attack and stroke.

The Mechanism

The word “diabetes” in public conversation is almost always treated as a metabolic disease, something about glucose and insulin. The vascular biology tells a different story.

Chronic hyperglycemia and endothelial injury. Elevated glucose generates reactive oxygen species through a process called advanced glycation, and these molecules directly impair endothelial nitric oxide production. The endothelium is the single-cell lining of every artery in the body. When it loses the ability to produce nitric oxide, it loses the ability to regulate vascular tone, resist platelet adhesion, and prevent inflammatory cell infiltration. Advanced glycation end-products (AGEs) accumulate in the arterial wall, reducing vascular compliance and promoting sustained, low-grade inflammation. A man with a hemoglobin A1c of 8.5 has been exposing his arterial endothelium to this hyperglycemic environment every hour for months or years before the number is measured.

The atherogenic lipid pattern. Insulin resistance causes the liver to overproduce very low-density lipoprotein (VLDL) particles. This drives triglycerides up, HDL down, and shifts the LDL particle distribution toward the small, dense subtype that penetrates the subendothelial space most readily. ApoB, which is the protein coat on every atherogenic lipoprotein particle, rises above what a standard LDL measurement suggests. This is the standard lipid pattern of type 2 diabetes and it is one of the most potent drivers of atherosclerosis progression known. LDL alone underestimates cardiovascular risk in these patients.

Autonomic neuropathy and silent ischemia. Diabetes damages the autonomic nerves, including those that carry the pain signals of cardiac ischemia. A diabetic man can have significant myocardial ischemia or even an acute MI without chest pain. The first symptom may be dyspnea, fatigue, or vague upper abdominal discomfort that he attributes to indigestion. This phenomenon, called silent ischemia, is why cardiac screening in diabetic men requires a lower threshold even in the absence of classic symptoms.

Coagulation and platelet abnormalities. Chronic hyperglycemia also increases platelet reactivity and promotes a pro-thrombotic coagulation state. This compounds the atherosclerotic plaque risk: not only do plaques form more readily, but when they rupture, the clot that forms on the ruptured surface is more aggressive. This is one of the reasons diabetic patients tend to have larger myocardial infarctions and higher in-hospital mortality when an event does occur.

The cumulative result: men with type 2 diabetes have approximately two to four times the coronary heart disease risk of men without it at equivalent ages and risk factor burdens. In some analyses, the cardiovascular risk of a diabetic man without prior cardiac events equals the risk of a non-diabetic man who has already had a heart attack. 5 / Solid This is why current guidelines from the American Diabetes Association and the American Heart Association treat diabetes as a cardiovascular disease risk equivalent.

What the Evidence Shows

The clinical trial evidence in this space is unusually strong, driven by a class of medications that were studied for cardiovascular outcomes, not just glucose control.

The EMPA-REG OUTCOME trial (2015). Zinman and colleagues enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease and randomized them to empagliflozin (an SGLT2 inhibitor) or placebo. The SGLT2 inhibitor works by blocking glucose reabsorption in the kidney, causing glucose to be excreted in urine. Results: 14 percent relative reduction in the primary composite cardiovascular endpoint. Cardiovascular mortality reduced by 38 percent. Heart failure hospitalization reduced by 35 percent. (Zinman et al. 2015, NEJM) 5 / Solid

The cardiovascular benefit appeared early, within weeks of starting the medication, faster than could be explained by glucose lowering alone. The leading hypothesis is that SGLT2 inhibitors reduce cardiac preload and afterload through their diuretic effect, reduce visceral fat, and may have direct myocardial protective effects through ketone body utilization.

The CANVAS program (2017) and DECLARE-TIMI 58 trial (2019). These confirmed cardiovascular and heart failure benefits across two other SGLT2 inhibitors, canagliflozin and dapagliflozin. The heart failure hospitalization reduction has been the most consistent finding across all three trials. Dapagliflozin’s benefit extended into patients without established cardiovascular disease in DECLARE-TIMI 58, suggesting the benefit is not limited to those who have already had a cardiac event. (Neal et al. 2017, NEJM; Wiviott et al. 2019, NEJM)

GLP-1 receptor agonist trials. The LEADER trial (2016) showed that liraglutide reduced major adverse cardiovascular events by 13 percent in patients with type 2 diabetes and high cardiovascular risk. The SUSTAIN-6 trial showed semaglutide reduced the same composite endpoint by 26 percent. (Marso et al. 2016, NEJM; Marso et al. 2016, NEJM) Beyond cardiovascular outcomes, these agents produce substantial weight loss, addressing the visceral adiposity that drives much of the metabolic and vascular pathology in type 2 diabetes.

Prediabetes as a cardiovascular risk state. The METSIM cohort and other longitudinal analyses confirm that cardiovascular risk elevation begins in the prediabetes range, before formal diabetes criteria are met. A fasting glucose of 108 and a hemoglobin A1c of 5.8 do not represent near-normal. They represent the early stage of the same vascular process that, at higher glucose, produces overt diabetic vascular disease. Fasting insulin rises before glucose does. A man with fasting insulin above 15 microunits per mL and a normal glucose has the insulin resistance that will produce glucose elevation and the atherogenic lipid pattern if the underlying process is not addressed.

Does intensive glucose control reduce cardiovascular events? This is a more nuanced question than most patients expect, and the answer has evolved. The ACCORD trial (Action to Control Cardiovascular Risk in Diabetes), published in 2008, randomized 10,251 patients with type 2 diabetes and high cardiovascular risk to intensive glucose control (targeting A1c below 6 percent) versus standard control (A1c 7 to 7.9 percent). The intensive arm had higher all-cause mortality, driven by cardiovascular deaths. The trial was stopped early. (Action to Control Cardiovascular Risk in Diabetes Study Group, NEJM 2008)

The implication is clinically important: aggressively lowering blood glucose does not necessarily lower cardiovascular events, particularly in patients with long-standing diabetes and established cardiovascular disease. The cardiovascular benefit in type 2 diabetes comes from the specific medications with outcomes trial evidence (SGLT2 inhibitors and GLP-1 agonists), not from glucose lowering per se. A patient whose A1c is pushed below 6.5 on a regimen that does not include one of these classes has achieved a glucose target, not a cardiovascular target. These are different goals and they require different treatments.

The UKPDS (UK Prospective Diabetes Study), which enrolled patients with newly diagnosed type 2 diabetes and followed them for decades, did find a modest cardiovascular benefit from early glucose control, particularly with metformin in overweight patients. The distinction between ACCORD and UKPDS is patient population: early diabetes with shorter duration responds differently to glucose lowering than longstanding disease with established cardiovascular risk. The lesson is not that glucose control is irrelevant but that it is not the primary cardiovascular intervention in high-risk patients with established disease.

SGLT2 Inhibitors Beyond Diabetes: When the Indication Crossed Over

The cardiovascular evidence for SGLT2 inhibitors did not stop with diabetes. A second wave of trials enrolled patients with heart failure regardless of diabetes status and found the same pattern of benefit, establishing these agents as cardiac medications with metabolic effects rather than metabolic medications with cardiac effects.

DAPA-HF (McMurray et al., New England Journal of Medicine, 2019) enrolled 4,744 patients with heart failure with reduced ejection fraction and randomized them to dapagliflozin or placebo. Critically, 45 percent of enrolled patients did not have type 2 diabetes. The primary composite of cardiovascular death, worsening heart failure, or hospitalization for heart failure was reduced by 26 percent in the dapagliflozin group (hazard ratio 0.74; 95% CI 0.65 to 0.85). The benefit was essentially identical in the diabetic and non-diabetic subgroups, confirming that the cardiac effect was not mediated through glucose lowering. Dapagliflozin became a Class I recommendation for all patients with HFrEF regardless of diabetes status in subsequent ESC and ACC/AHA heart failure guidelines. 5 / Solid

EMPEROR-Reduced (Packer et al., NEJM, 2020) confirmed the same finding with empagliflozin in HFrEF, reducing the composite of cardiovascular death and heart failure hospitalization by 25 percent (hazard ratio 0.75; 95% CI 0.65 to 0.86). Again, the benefit was consistent regardless of diabetes status.

The EMPEROR-Preserved trial (Anker et al., NEJM, 2021) extended this to heart failure with preserved ejection fraction, the form of heart failure predominant in women and the condition that had resisted all prior attempts at disease modification. Empagliflozin reduced the composite of cardiovascular death and heart failure hospitalization by 21 percent in HFpEF patients (hazard ratio 0.79; 95% CI 0.69 to 0.90). DELIVER (Solomon et al., NEJM, 2022) confirmed this with dapagliflozin in HFpEF. These were the first large randomized trials to demonstrate significant event reduction in HFpEF, providing a drug class with evidence for the most common heart failure presentation in women.

For a man with type 2 diabetes and any form of heart failure, the question is no longer simply what will control blood sugar. The question is which heart failure-specific regimen is optimal, and for most patients, an SGLT2 inhibitor now occupies a central position in the answer independent of glycemic targets.

What to Do This Week

1. If you have type 2 diabetes and are not currently taking an SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) or a GLP-1 receptor agonist (semaglutide or liraglutide), ask your physician specifically whether one is appropriate for your cardiovascular risk profile. These are cardiovascular medications that also lower glucose. The conversation belongs in the cardiovascular risk frame, not just the glucose management frame.

2. If you have type 2 diabetes and have not had an ApoB measured, request it at your next laboratory visit. The atherogenic lipid pattern of diabetes is better characterized by ApoB than by LDL-C alone. A man with an LDL of 90 and an ApoB of 130 has a substantially different risk profile than his LDL alone suggests.

3. If you have prediabetes, treat it as a cardiovascular risk state, not a pre-disease holding category. Three measurements that most accurately characterize how much vascular risk is already accumulating: fasting insulin, waist circumference, and ApoB. Ask for all three.

4. Know the atypical symptoms of MI that are more common in diabetic patients: jaw discomfort, upper abdominal discomfort, unexplained sweating, profound fatigue without exertion, or new shortness of breath. If any of these occur in the context of physical activity or emotional stress, treat them with the same urgency as chest pain.

5. If you have been told your hemoglobin A1c is “a little high” or “borderline,” ask your physician to measure your fasting insulin and your ApoB. A1c alone does not characterize the full vascular risk. The insulin level tells you how hard the pancreas is working to compensate, and the ApoB tells you what is happening in the arterial wall as a result.

Statin therapy in diabetes: underutilized. The ACC/AHA guidelines recommend statin therapy for all adults with type 2 diabetes aged 40 to 75 who have an LDL above 70 mg/dL, regardless of calculated 10-year cardiovascular risk. Multiple statin trials specifically in diabetic subgroups have confirmed risk reduction. The Heart Protection Study enrolled 5,963 patients with diabetes and found that simvastatin 40 mg reduced major cardiovascular events by 22 percent, with similar proportional benefit regardless of baseline LDL. (Collins et al. 2003, Lancet) Despite this evidence, statin use remains lower than guideline recommendations in diabetic patients in multiple real-world analyses. If you have type 2 diabetes and are not on a statin, the question of why deserves a clear answer from your physician.

Cardiovascular risk scoring in diabetes. Standard 10-year cardiovascular risk calculators (the ACC/AHA Pooled Cohort Equations) use diabetes as a yes/no binary input. They do not capture diabetes duration, glycemic control quality, presence of microvascular complications, or the atherogenic lipid pattern’s severity. Two diabetic men with the same traditional risk factor profile can have substantially different actual cardiovascular risk depending on these variables. This is why diabetes specialists and cardiologists who work together tend to use coronary artery calcium (CAC) scoring as an additional tool in diabetic patients with intermediate calculated risk. A diabetic man whose CAC score is zero has a substantially different near-term event probability than one with a CAC score of 400, even if their 10-year Pooled Cohort Equation risk appears similar.

Type 2 diabetes is a vascular disease with a glucose component, not the reverse. The men who understand this distinction treat it accordingly, and the clinical outcomes data suggest they live longer because of it.